56416 
Federal Register / Vol. 5G, No. 213 / Monday. November 4, 1991 / Notices 
Recombinant DNA Advisory Committee 
for formal review and approval. The title 
of this protocol is: “Lymphokine Gene 
Therapy of Cancer Phase I Study of 
Tumor Immunotherapy with Autologous 
Fibroblasts Genetically Modified to 
Secrete Interleukin-2." 
V. Addition to Appendix D of the “NIH 
Guidelines” Regarding a Human Gene 
Therapy Protocol/Dr. Greenberg 
In a letter dated October 8. 1991, Dr. 
Philip D. Greenberg of the University of 
Washington. Seattle, indicated his 
intention to submit a human gene 
therapy protocol to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA Advisory Committee 
for formal review and approval. The title 
of this protocol is: “A Phase I/II Study of 
Cellular Adoptive Immunotherapy Using 
Genetically Modified CD8+ HIV- 
Specific T Cells for HIV-Seropositive 
Patients Undergoing Allogeneic Bone 
Marrow Transplant." 
VI. Report from the Working Group on 
Data Management 
At the last Human Gene Therapy 
Subcommittee meeting on July 30-31. 
1991, the subcommittee formed a 
Working Group on Data Management. 
The working group was charged with 
developing a system for analyzing 
approved protocol results for the 
purpose of ensuring quality control in 
the approval process. 
The Human Gene Therapy 
Subcommittee will receive a report from 
this working group during its meeting on 
November 21-22, 1991. 
VII. Report From the Working Group on 
New Approaches to Gene Therapy 
At the last Human Gene Therapy 
Subcommittee meeting on July 30-31, 
1991. the subcommittee formed a 
Working Group on New Approaches to 
Gene Therapy. The working group was 
charged with gathering information 
about the past literature on human germ 
line gene therapy. Another issue to be 
considered involves selection of 
speakers who would discuss basic 
science research that is relevant to germ 
line gene therapy. 
The Human Gene Therapy 
Subcommittee will receive a report from 
this working group during its meeting on 
November 21-22, 1991. 
VIII. Report From the Working Group on 
the Future Role of the Recombinant 
DNA Advisory Committee 
At the last Human Gene Therapy 
Subcommittee on July 30-31, 1991. the 
subcommittee requested that the 
Working Group on the Future Role of the 
Recombinant DNA Advisory Committee 
prepare a report about the feasibility of 
merging the Human Gene Therapy 
Subcommittee and the Recombinant 
DNA Advisory Committee. 
The Human Gene Therapy 
Subcommittee will receive a report from 
this working group during its meeting on 
November 21-22, 1991. 
IX. Other Matters To Be Considered by 
the Committee 
Protocols which are approved by the 
Human Gene Therapy Subcommittee 
will be forwarded to the Recombinant 
DNA Advisory Committee for 
consideration during its February 10-11. 
1992, meeting. 
Attendance by the public will be 
limited to space available. Members of 
the public wishing to speak at this 
meeting may be given such opportunity 
at the discretion of the Chair. 
Dr. Nelson A. Wivel, Director, Office 
of Recombinant DNA Activities, 
National Institutes of Health, Building 
31, Room 4B11, Bethesda, Maryland 
20892, telephone (301) 490-9838, FAX 
(301) 496-9839, will provide materials to 
be discussed at this meeting, roster of 
committee members, and substantive 
program information. A summary of the 
meeting will be available at a later date. 
OMB's "Mandatory Information 
Requirements for Federal Assistance 
Program Announcements” (45 FR 39592. 
June 11, 1980) requires a statement 
concerning the official government 
programs contained in the Catalog of 
Federal Domestic Assistance. Normally 
NIH lists in its announcements the 
number and title of affected individual 
programs for the guidance of the public. 
Because the guidance in this notice 
covers not only virtually every NIH 
program but also essentially every 
Federal research program in which DNA 
recombinant molecule techniques could 
be used, it has been determined not to 
be cost effective or in the public interest 
to attempt to list these programs. Such a 
list would likely require several 
additional pages. In addition, NIH could 
not be certain that every Federal 
program would be included as many 
Federal agencies, as well as private 
organizations, both national and 
international, have elected to follow the 
NIH Guidelines. In lieu of the individual 
program listing, NIH invites readers to 
direct questions to the information 
address above about whether individual 
programs listed in the Catalog of 
Federal Domestic Assistance are 
affected. 
Dated: October 29. 1991. 
Raymond Bahor, 
Acting Committee Management Officer. NIH. 
(FR Doc. 91-26481 Filed 11-1-91: 8:45 am| 
BILLING CODE 4140-01-M 
DEPARTMENT OF HOUSING AND 
URBAN DEVELOPMENT 
Office of the Secretary 
[Docket No. D-91-970; FR-3172-D-011 
Delegation of Authority for the HOME 
Investment Partnerships (HOME) 
Program, Other than the Indian Tribe 
Component of the HOME Program 
agency: Office of the Secretary, HUD. 
ACTION: Notice of delegation of 
authority. 
SUMMARY: This notice delegates to the 
Assistant Secretary for Community 
Planning and Development the 
Secretary’s power and authority with 
respect to theTIOME Investment 
Partnerships (HOME) Program, subject 
to specified exceptions. The delegation 
of authority does not include the power 
and authority to administer the HOME 
Program with respect to Indian tribes. 
EFFECTIVE DATE: October 28, 1991. 
FOR FURTHER INFORMATION CONTACT: 
Mary Kolesar, Office of Urban 
Rehabilitation. 451 Seventh Street. SW.. 
Washington. DC 20410, telephone (202) 
708-2470, TDD (202) 708-2565. (These 
are not toll-free numbers.) 
SUPPLEMENTARY INFORMATION: This 
notice states the scope of the authority 
of the Assistant Secretary for 
Community Planning and Development 
for the HOME Program. All of the 
Secretary’s power and authority is 
delegated, except for the component of 
the HOME Program involving Indian 
tribes (which is delegated to the 
Assistant Secretary for Public and 
Indian Housing by a separate delegation 
published elsewhere in today's Federal 
Register). The authority delegated may 
be redelegated to employees of the 
Department, except for the authority to 
issue or waive rules and regulations. 
•The HOME Program is a new program 
authorized by the HOME Investment 
Partnerships Act (Pub. L 101-625, title II. 
104 Stat. 4079, 4094-4128 (November 28. 
1990), codified at 42 U.S.C. 12721-12839). 
In general, under the HOME Program, 
funds are allocated by formula among 
eligible state and local governments that 
qualify as participating jurisdictions to 
develop affordable housing for low- 
income and very low-income families. 
HOME funds are also made available. 
[ 220 ] 
Recombinant DNA Research, Volume 15 
